These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31259807)

  • 21. Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials.
    Jackson TL; Haller J; Blot KH; Duchateau L; Lescrauwaet B
    Surv Ophthalmol; 2022; 67(3):697-711. PubMed ID: 34480895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.
    Cacciamani A; Gattegna R; Pileri M; Di Nicola M; Bardanzellu S; Facciolo G; Cosimi P; Govetto A; Scarinci F
    Int Ophthalmol; 2020 Jan; 40(1):185-193. PubMed ID: 31565760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BASELINE CHARACTERISTICS OF VITREOMACULAR TRACTION PROGRESSING TO FULL-THICKNESS MACULAR OR LAMELLAR HOLES IN THE PHASE III TRIALS OF ENZYMATIC VITREOLYSIS.
    Schneider EW; Jaffe GJ
    Retina; 2020 Aug; 40(8):1579-1584. PubMed ID: 31415451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US.
    Khanani AM; Dugel PU; Haller JA; Wagner AL; Lescrauwaet B; Schmidt R; Bennison C
    J Comp Eff Res; 2020 Mar; 9(4):287-305. PubMed ID: 31961196
    [No Abstract]   [Full Text] [Related]  

  • 26. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
    Abou Ltaif S; Herbert L
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resolution of outer retinal abnormalities in eyes with vitreomacular traction without macular hole in the OASIS trial.
    Thomas AS; Duchateau L; Kozma-Wiebe P; Jaffe G
    Br J Ophthalmol; 2023 Jul; 107(7):1012-1017. PubMed ID: 35288439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
    Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
    Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection.
    Katz RS
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(3):239-42. PubMed ID: 24708167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
    Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
    Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial.
    Lavine JA; Srivastava SK; Dukles N; Reese JL; Ehlers JP
    Br J Ophthalmol; 2020 Mar; 104(3):410-415. PubMed ID: 31248879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ocriplasmin on the management of macular holes: assessment of the clinical relevance of ocriplasmin.
    Moisseiev J; Moroz I; Katz G
    JAMA Ophthalmol; 2014 Jun; 132(6):709-13. PubMed ID: 24723009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter-Reichart S; Mennel S
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASSESSMENT OF ANATOMICAL AND FUNCTIONAL OUTCOMES WITH OCRIPLASMIN TREATMENT IN PATIENTS WITH VITREOMACULAR TRACTION WITH OR WITHOUT MACULAR HOLES: Results of OVIID-1 Trial.
    Tadayoni R; Holz FG; Zech C; Liu X; Spera C; Stalmans P
    Retina; 2019 Dec; 39(12):2341-2352. PubMed ID: 30308558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Intravitreal Ocriplasmin on Hue Discrimination.
    Neffendorf JE; Kirthi V; Soare C; Jackson TL
    Optom Vis Sci; 2021 Dec; 98(12):1394-1399. PubMed ID: 34905526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
    Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA;
    Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
    Luttrull JK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.
    Chatziralli I; Theodossiadis G; Xanthopoulou P; Miligkos M; Sivaprasad S; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1247-56. PubMed ID: 27137631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment.
    Liang IC; Wang K; Chien HW; Lin SY
    Indian J Ophthalmol; 2016 Mar; 64(3):222-4. PubMed ID: 27146933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.